Physician profile
Robert C Nelson
NPI 1023006632
$3,353.49
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,172 · 2020: $514 · 2021: $539 · 2022: $856 · 2023: $150 · 2024: $122.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $272.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $272.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,148.33 | 2019-2022 | |
| Allergan, INC. | $585.19 | 2020-2022 | |
| Genentech USA, INC. | $273.16 | 2020-2023 | Vabysmo |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $257.91 | 2019-2021 | |
| Kala Pharmaceuticals, INC. | $163.56 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $147.94 | 2020-2022 | |
| Sun Pharmaceutical Industries INC. | $146.13 | 2019-2022 | |
| Sight Sciences, INC. | $138.74 | 2022 | |
| Apellis Pharmaceuticals, INC. | $122.12 | 2024 | Syfovre |
| Glaukos Corporation | $112.63 | 2022 | |
| Aerie Pharmaceuticals, INC. | $89.92 | 2020 | |
| Bausch & Lomb Americas INC. | $81.78 | 2022 | |
| Shire North American Group INC | $24.88 | 2019 | |
| Coopervision INC. | $16.04 | 2022 | |
| Oyster Point Pharma, INC. | $15.05 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $12.37 | 2022 | |
| Eyevance Pharmaceuticals LLC | $12.25 | 2019 | |
| Quidel Corporation | $5.49 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Nelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.